Fondaparinux (Arixtra) is a synthetic anticoagulant based on a pentasaccharide sequence that forms the minimal antithrombin (AT) binding region of heparin. Like low molecular weight heparin, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all. Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be beneficial in certain settings. Indications for fondaparinux include deep vein thrombosis and pulmonary embolism and superficial vein thrombosis.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ@ https://www.alliedmarketresearch.com/request-toc-and-sample/10859

An increase in the number of mergers and acquisitions is expected to help the industry grow in the coming years. For example, in September 2020, Mylan planned a megamerger with Pfizer’s Upjohn generics unit. Mylan will pay $756 million for the European rights to Aspen Pharmacare’s sterile injectable anticoagulants, worth about a quarter of a billion dollars.

Growth in number of product launches would help the industry flourish during the forecast period. For instance, in December 2017, Aurobindo Pharma received final approval from US health regulators to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent deep vein thrombosis. The approval by US Food & Drug Administration (USFDA) is for multiple strengths of Fondaparinux Sodium injection of 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes. This is the 52nd ANDA (including 2 tentative approvals) to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable and ophthalmic products

๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ@ https://www.alliedmarketresearch.com/purchase-enquiry/10859

๐Š๐ž๐ฒ ๐…๐ข๐ง๐๐ข๐ง๐ ๐ฌ

  • This study presents the analytical depiction of the global Fondaparinuxindustry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Fondaparinuxmarket share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Fondaparinuxmarket growth scenario.
  • Porterโ€™s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Fondaparinuxmarket analysis based on competitive intensity and how the competition will take shape in coming years.

๐‚๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ@ https://www.alliedmarketresearch.com/request-for-customization/10859

๐‹๐ž๐š๐๐ข๐ง๐  ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ:
Bayer Healthcare AG,, GlaxoSmithKline plc.,, Boehringer Ingelheim,, Sanofi S.A.,, Apotex,, Abbott India Limited,, Aspen Holdings,, Pfizer Inc.,, Bristol-Myers Squibb Company,, Eisai Inc.,, WisMed Pharmaceuticals, Kaifeng Pharmaceutical.

๐‘๐ž๐ฅ๐š๐ญ๐ž๐ ๐๐ฅ๐จ๐ :

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Leave a comment

Your email address will not be published. Required fields are marked *